Table 2.

Ki67 expression in biopsy and surgical specimens

Pre-rosiglitazone (mean)Post-rosiglitazone (mean)Δpre-post (Δmean)*
<5<5
<5<5
55
70-90 (80)70-90 (80)↔ (↔)
5-10 (7.5)5-10 (7.5)↔ (↔)
70-80 (75)70-80 (75)↔ (↔)
20-40 (30)20-40 (30)↔ (↔)
10-30 (20)10-30 (20)↔ (↔)
60-90 (75)60-90 (75)↔ (↔)
30-50 (40)30-50 (40)↔ (↔)
5-10 (7.5)5-10 (7.5)↔ (↔)
105-10 (7.5)↔ (↓)
5-10 (7.5)5↔ (↓)
20-40 (30)20-30 (25)↔ (↓)
40-60 (50)30-50 (40)↔ (↓)
10-39 (20)5-10 (7.5)↔ (↓)
10-30 (20)10-20 (15)↔ (↓)
0-10 (5)<5↔ (↓)
1010-20 (15)↔ (↑)
5-10 (7.5)10-20 (15)↔ (↑)
30-40 (35)30-50 (40)↔ (↑)
10-30 (20)20-30 (25)↔ (↑)
10-20 (15)20-40 (30)↔ (↑)
5-10 (7.5)10-20 (15)↔ (↑)
1010-20 (15)↔ (↑)
10-20 (15)5↓ (↓)
20-30 (25)5↓ (↓)
20-40 (30)5-10 (7.5)↓ (↓)
105
20-30 (25)<1↓ (↓)
5-10 (7.5)<5↓ (↓)
<110
  • NOTE: Ki67 expression was assessed as percentage of cell nuclei with immunostaining in 32 evaluable cases, with the range of staining indicated for instances of heterogeneity. Change (Δ) between pretreatment and posttreatment values is indicated as increased (↑), decreased (↓), or unchanged (↔). Unchanged values include those with overlap between ranges of pretreatment and posttreatment staining.

  • * P nonsignificant at >0.05.